Moderna’s COVID-19 Vaccine Candidate Delivers Efficacy of 94.5% in Phase 3 Study ...Middle East

Thepintree.net - News
Moderna’s COVID-19 Vaccine Candidate Delivers Efficacy of 94.5% in Phase 3 Study
Cambridge, Mass…Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Dise

Read More Details
Finally We wish PressBee provided you with enough information of ( Moderna’s COVID-19 Vaccine Candidate Delivers Efficacy of 94.5% in Phase 3 Study )

Also on site :